SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001213900-17-012849
Filing Date
2017-12-01
Accepted
2017-12-01 16:22:36
Documents
1
Group Members
ENRICO CAVAZZAFRANCESCA CAVAZZALEADIANT BIOSCIENCES, INC.MARTINA CAVAZZA PRETAPAOLO CAVAZZASILVIA CAVAZZA

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 5 TO SCHEDULE 13D sc13d1117a5essetif_soligenix.htm SC 13D/A 392059
  Complete submission text file 0001213900-17-012849.txt   394000
Mailing Address 29 EMMONS DRIVE SUITE C-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE C-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Subject) CIK: 0000812796 (see all company filings)

IRS No.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-39976 | Film No.: 171234434
SIC: 2834 Pharmaceutical Preparations

Mailing Address VIA SUDAFRICA 20 ROME L6 00144
Business Address
Essetifin SPA (Filed by) CIK: 0001092601 (see all company filings)

Fiscal Year End: 1231
Type: SC 13D/A